Cours Protalix Biotherapeutics Inc TEL AVIV STOCK EXCHANGE
Actions
US74365A1016
Recherche biotechnologique et médicale
CA 2024 * | 52,7 M 19,33 Md 47,42 M | CA 2025 * | 101 M 37,19 Md 91,24 M | Capitalisation | 82,85 M 30,39 Md 74,55 M |
---|---|---|---|---|---|
Résultat net 2024 * | - | Résultat net 2025 * | 54 19,81 k 48,59 | VE / CA 2024 * | 1,57 x |
Trésorerie nette 2024 * | - 0 0 | Trésorerie nette 2025 * | - 0 0 | VE / CA 2025 * | 0,82 x |
PER 2024 * |
9,42
x | PER 2025 * |
1,79
x | Employés | - |
Rendement 2024 * |
-
| Rendement 2025 * |
-
| Flottant | 90,27% |
Dernier transcript sur Protalix Biotherapeutics Inc
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Dror Bashan
CEO | Chief Executive Officer | 57 | 30/06/19 |
Eyal Rubin
DFI | Director of Finance/CFO | 48 | 22/07/19 |
Yael Hayon
CTO | Chief Tech/Sci/R&D Officer | 41 | 05/07/20 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Pol Boudes
BRD | Director/Board Member | 67 | 01/12/19 |
Gwen Melincoff
BRD | Director/Board Member | 72 | 01/12/19 |
Aharon Schwartz
BRD | Director/Board Member | 80 | 01/11/14 |
Varia. 1 janv. | Capi. | |
---|---|---|
+29,77% | 49,18 Md | |
+1,00% | 42,11 Md | |
+50,47% | 40,37 Md | |
-5,26% | 28,85 Md | |
+13,68% | 26,09 Md | |
-22,99% | 18,71 Md | |
+8,22% | 13,26 Md | |
+32,41% | 12,32 Md | |
-1,62% | 11,99 Md |